Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz

Antiviral Therapy

Volumn 9, Issue 5, 2004, Pages 721-728

  Van Leth, Frank ^a   Conway, Brian ^b   Laplumé, Hector ^c   Martin, Des ^d   Fisher, Martin ^e   Jelaska, Ante ^f   Wit, Ferdinand W ^a   Lange, Joep M A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^d Toga Laboratories   (South Africa)

^e UK   (United Kingdom)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOMES RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; SCORING SYSTEM; SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEVIRAPINE; OXAZINES; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 7244226596     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL & Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 30:105-110.
2. Mannheimer S, Friedland G, Matts J, Child C & Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clincal Infectious Diseases 2002; 34:1115-1121.
3. WHO. Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: WHO, 2003.
4. van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW & Lange JM; 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004; 363:1248-1250.
5. Wu AW, Revicki DA, Jacobson D & Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Quality of Life Research 1997; 6:481-493.
6. Revicki DA, Sorensen S & Wu AW Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Medical Care 1998; 36:126-137.
7. AIDS Clinical Trial Group. Table of Grading Severity of Adult Adverse Experiences: Division of AIDS. Rockville: National Institute of Allergy and Infectious Diseases, 1996.
8. Bucciardini R, Wu AW, Floridia M, Fragola V, Ricciardulli D, Tomino C, Weimer LE, Pirillo MF, Mirra M, Marzi M, Giannini G, Galluzzo CM, Andreotti M, Massella M & Vella S; Istituto Superiore di Sanita 047 Study. Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. AIDS 2000; 14:2567-2574.
9. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ & Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000; 14:807-812.
10. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldra A, Balague M, Johnston S, Arno A, Jou A, Tural C, Sirera G, Romeu J & Clotet B. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases 2002; 34:504-510.
11. Fumaz CR, Tuldra A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo E, Romeu J, Sirera G, Tural C & Clotet B. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. Journal of Acquired Immune Deficiency Syndromes 2002; 29:244-253.
12. Lochet P, Peyriere H, Lotthe A, Mauboussin JM, Delmas B & Reynes J. Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. HIV Medicine 2003; 4:62-66.
13. Weinfurt KP, Willke RJ, Click HA, Freimuth WW & Schulman KA. Relationship between CD4 count, viral burden, and quality of life over time in HIV-1-infected patients. Medical Care 2000; 38:404-410.
14. Call SA, Klapow JC, Stewart KE, Westfall AO, Mallinger AP, DeMasi RA, Centor R & Saag MS. Health-related quality of life and virologic outcomes in an HIV clinic. Quality of Life Research 2000; 9:977-985.
15. Murri R, Fantoni M, Del Borgo C, Visona R, Barracco A, Zambelli A, Testa L, Orchi N, Tozzi V, Bosco O & Wu AW. Determinants of health-related quality of life in HIV-infected patients. AIDS Care 2003; 15:581-590.
16. Pollard RB, Robinson P & Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clinical Therapeutics 1998; 20:1071-1092.
17. Murphy RL. Defining the toxicity profile of nevirapine and other antiretroviral drugs. Journal of Acquired Immune Deficiency Syndromes 2003; 34(Suppl 1.):S15-20.
18. Stern JO, Robinson PA, Love J, Lanes S, Imperiale MS & Mayers DL. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. Journal of Acquired Immune Deficiency Syndromes 2003; 34(Suppl 1.):S21-33.
19. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J & Clotet B; Spanish Lipodystrophy Group. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes 2001; 27:229-236.
20. Raboud JM, Singer J, Thorne A, Schechter MT & Shafran SD. Estimating the effect of treatment on quality of life in the presence of missing data due to drop-out and death. Quality of Life Research 1998; 7:487-494.
21. Wu AW, Jacobson DL, Berzon RA, Revicki DA, van der Horst C, Fichtenbaum CJ, Saag MS, Lynn L, Hardy D & Feinberg J. The effect of mode of administration on medical outcomes study health ratings and EuroQol scores in AIDS. Quality of Life Research 1997; 6:3-10.